The New York State Drug Utilization Review (DUR) Board

April 27, 2016 in Albany

Meeting Objective

To recommend preferred and non-preferred drugs based on clinical reviews and financial information.

NYS Capitol Albany New York featuredDUR will review Direct Acting Antivirals for Hepatitis C, including Copegus (ribavirin), Daklinza (daclatasvir), Harvoni (ledipasvir/sofosbuvir), Moderiba (ribavirin), Olysio (simeprevir), Rebetol (ribavirin), Ribapak (ribavirin), Ribasphere (ribavirin), ribavirin, Sovaldi (sofosbuvir), Technivie (ombitasvir/paritaprevir/ ritonavir), Viekira Pak (ombitasvir/paritaprevir/ritonavir/ dasabuvir), Zepatier (elbasvir and grazoprevir).

DUR will also review drug utilization in the fee-for-service (FFS) and managed care programs and current clinical criteria in the FFS program.

VOCAL-NY and community leaders will attend the meeting to advocate for unrestricted access to Hepatitis C drug coverage.  Transportation will be provided from NYC for those who would like to participate. For more information and to register for a bus seat, email Carlos Rosario at

View the meeting agenda here



We're not around right now. But you can send us an email and we'll get back to you. Thank you.


©2019 HepFree.NYC. All rights reserved. Site by Lookit Design QuikSite®


Log in with your credentials

Forgot your details?